DR3:TL1A Assay Service
●
Target
DR3:TL1A
●
Description
Screening and/or profiling compounds that inhibit the interaction between DR3 and TL1A in a biochemical assay.
●
Synonyms
TNF ligand-related molecule 1, Vascular endothelial cell growth inhibitor, Tumor necrosis factor ligand superfamily member 15, TL1, VEGI, TNFSF15, Death Receptor 3, TNF-like ligand 1A
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
Luminescent
●
Reference Compounds and IC50
TL1A Neutralizing Antibody, 6 nM
●
Assay Principle
The DR3:TL1A Inhibitor Screening Assay is designed for screening and profiling inhibitors of the interaction between DR3 (Death Receptor 3) and TL1A (TNF-like ligand 1A). First, DR3 is coated on a 96-well plate. Next, biotinylated TL1A is incubated with DR3. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence. The chemiluminescence signal is proportional to the binding of DR3:TL1A.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
O95150
●
Background
DR3 (death receptor 3), also known as tumor necrosis factor receptor superfamily member 25 or TNFRSF25, is a membrane receptor of the tumor necrosis factor receptor superfamily of proteins (TNFRSF), which associates with TL1A (TNF-like protein 1A) in T and NK cells. DR3 has been recognized as a significant anti-apoptotic and differentiation factor and it is a co-stimulatory receptor. TL1A, also called TNFSF15, is a member of the tumor necrosis factor family. It is expressed in different immune cells, such as monocyte, macrophage, dendritic cell, T cell and non-immune cells. TL1A competitively binds to DR3, having a higher affinity for DcR3 (decoy receptor 3), providing stimulatory signal for downstream signaling pathways. It then regulates proliferation, activation, apoptosis, and chemokine production in effector cells. The role of DR3 in T cell activation, and consequently in cytokine secretion and cell proliferation, makes it an attractive target in cancer therapy. Inhibition of DR3-TL1A interaction has substantial therapeutic potential in the treatment of solid tumors.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
